

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2014

IMPRIMIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35814
(Commission
File Number)

45-0567010
(IRS Employer
Identification No.)

12626 High Bluff Dr. Ste 150
San Diego, CA
(Address of principal executive offices)

92130
(Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

N/A

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

Attached as Exhibit 99.1 to this Item 7.01 is a presentation that is being used by the management of Imprimis Pharmaceuticals, Inc. (the "Company") in meetings describing the Company.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Presentation dated September 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMPRIMIS PHARMACEUTICALS, INC.

Dated: September 17, 2014

By: /s/ Andrew R. Boll

Name: Andrew R. Boll

Title: Vice President, Accounting and Public Reporting

EXHIBIT INDEX

99.1 Presentation dated September 2014

INTRODUCTION TO IMPRIMIS PHARMACEUTICALS NASDAQ: IMMY

MARK L. BAUM, CEO

SEPTEMBER 2014

CRAIG-HALLUM 2014 ALPHA SELECT CONFERENCE

This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Some of these risks and uncertainties include, but are not limited to: the Company's ability to make commercially available its formulations and technologies in a timely manner or at all; market acceptance of the Company's formulations and challenges related to the marketing of the Company's formulations; the Company's ability to enter into strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Imprimis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

VISION

To deliver customized and other novel medicines to physicians and patients **TODAY** at accessible prices.

MARKET IN NEED OF A SOLUTION



OCULAR SURGERY MARKET

- Standard of care is self-administered steroid, NSAID and antibiotic eye drop therapy
- Significant patient compliance issues; high cost to patients; and increased staff time required for patient counseling
- Physicians and patients are dissatisfied with post cataract surgery eye drop therapy

How do you reduce reliance on eye drops?

OUR NOVEL SOLUTION

- Single, simple step during the procedure
- >40,000 cases to date



Superior patent-pending technology allows for an elegant injectable formulation

CATARACT SURGERY ANIMATION




Courtesy of Dr. James Lewis



Since Our Go Dropless Launch in April 2014

- More than 100 ophthalmologists have been trained or have begun prescribing our formulations for their patients
- At leading eye meetings, physicians report >90% success in eliminating the use of post-operative eye drops
- Our patent pending ophthalmic formulations have been referenced in over 36 trade press print and on-line articles since January 2014
- During Q3 2014, Imprimis expects its Dropless therapy will be evaluated and/or initiated in ambulatory surgery centers representing over 50,000 cataract procedures annually
- Go Dropless™ education campaign is gathering momentum (www.GoDropless.com)

Training Portal Development and Website Relaunch



Online training portal provides new users with education on injection technique, special cases, and preparation



GoDropless.com gets a new look and feel, is optimized for mobile/tablet, and splits into patient and physician sites

“WHY GO DROPLESS” CAMPAIGN

SHORT COMPILATION OF 18 VIDEOS ON SITE



TRADE PRESS AD

**95% of Leading Cataract Surgeons
Would Prefer Dropless Therapy™**

GO DROP LESS™

William Trattler, MD
Ophthalmologist

WHY GO DROPLESS™

- Increase compliance
- Improve staff efficiency
- Reduce overall cost

Watch the rest of the videos and learn more at www.GoDropless.com

©2014 Imprimis Pharmaceuticals, Inc. All Rights Reserved. IMP001 08/14 Brought to you by **imprimis**

WEB BANNER AD – NEWSWIRE TO 20,000

GO DROP LESS™ **95% of Leading Cataract Surgeons
Surveyed Would Prefer Dropless Therapy**

FIND OUT WHY »

©2014 Imprimis Pharmaceuticals, Inc. All Rights Reserved. IMP001 08/14 **imprimis**

505(b)(2)

- Single generic drug (G)
- Combo of generic drugs (G+G)



Time
Expense
Inflexibility
Food & Drug Cosmetic Act (FDCA)

- Each formulation is patient-specific



Speed to market
Low-cost development
Flexibility
State Pharmacy Law & DQSA (2013)

OPHTHAMOLOGY

TriMoxi + TriMoxiVanc and Predisone-Moxifloxacin (PredMoxi)

Human

- Sterile Injection During Ocular Surgery
- Combination Eye Drops Post-LASIK Surgery

Animal

- *In Development* for Veterinarian Ocular Surgery

Compounded Mydriatics

- Lyophilized Epinephrine, Shugarcaine and Phenylephrine

Non-Proprietary Formulations

- *In Development* ... Compounded Avastin and Hyaluronidase
- Compounded Mitomycin

UROLOGY

Injectable Pentoxifylline

- Treatment for Peyronie's Disease

Ophthalmology

- **Competitors:** Bausch+Lomb (VRX); Allergan (AGN); Alcon (NVS)
- 3.6 million cataract surgeries annually in U.S. / 22 million globally
- US LASIK surgeries: 700,000 / year
- \$1B U.S. drug market (NSAID, steroid and antibiotic)
- Estimated average eye drop cost: \$300 - \$400 / procedure
- Estimated co-pay for Medicare patients: \$75 - \$125 / procedure

Urology (Peyronie's Disease)

- **Competitors:** Auxilium (AUXL), Teva (TEVA), Impax (IPXL), Apotex
- 1 in 11 men suffer from Peyronie's disease
- 95,000 men diagnosed annually
- \$1B U.S. drug market
- Leading competitor cost: \$3,300 (8 injections) - \$26,000 total

2014 and 2015 Strategic Goals

- **Grow ophthalmology division**
 - Continue adoption momentum
 - Build on novel ophthalmology portfolio
 - Normalize pricing with public and private payers by mid-2015
- **Monetize non-ophthalmology formulations**
 - Prepare for planned 2015 urology launch
 - Continue evaluation of proprietary formulations for expansion into other therapeutic markets
 - Build on non-proprietary formulations business
- **Execute prescription fulfillment strategy**
 - Scale business to establish national footprint
 - Optimize operational systems

Trading Symbol: NASDAQ: IMMY

Current Price per Share (9-10-14): \$7.94

Market Cap: \$70 Million

52-Wk Range: \$3.01 - \$9.62

Average Daily Trading Volume: 21,000 shares

- Clean capital structure
- No preferred shares or convertible debt; No significant debt
- Strong cash position - \$12M as of 6-30-2014
- Began to record revenue in Q2: \$668K
- Shift in Q2 expenses from R&D to Selling & Marketing

- Focused on proprietary sterile and topical drug formulations in the ophthalmology and urology therapeutic areas
- Unique business model de-risks pharmaceutical development
- Proprietary drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators
- Ophthalmology formulations now being used by leading surgeons during cataract and other ocular surgeries
- Orders fulfilled through recently-acquired pharmacy business - licensed to distribute in 33 states
- Plans to expand distribution network nationwide

QUESTIONS?

PRESENTATION BY:

Imprimis Pharmaceuticals, Inc.
(NASDAQ: IMMY)

12264 El Camino Real, #350
San Diego, CA 92130

Mark Baum
Founder, CEO and Board of Directors
(858) 704-4042
mark@imprimispharma.com

Investor Relations
Bonnie Ortega
Director of Investor Relations
(858) 704-4587
bortega@imprimispharma.com



